

Suzanne Rab, Counsel, Hogan Lovells

The Fourth International Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum



- NEW PHARM has a product which is protected by a basic patent (Product A). The patent is due to expire in 2012.
- NEW PHARM has products B, C, D and E under development and is considering whether C, D and E are patentable.
- NEW PHARM is aware that generic companies are considering launching generic alternatives to Product A when it comes off patent.
- NEW PHARM is considering various practices which may help to develop and extend the life of Product A.

#1


 File patent applications for new production processes for the production of active ingredients already covered by the basic patents for Product A

#2

 File patent applications for new reformulations with the aim of creating a multi-layered defence around the product towards the end of the patent protection period

#3

 Seek a patent for Product B to which it is intended patients will be "switched" by promotion before the expiry of the patent for Product A and then remove Product A from the market before the end of the period of patent protection for Product A



#5

 File patent applications for Products C, D and E with the aim of gaining an enforceable right but then withdraw the applications if they are challenged

#6

 Intervene in the marketing authorisation processes in Member States where generic companies are applying for authorisation, claiming that the products are inferior to Product A and less safe

#7

 Send letters to doctors, pharmacies and charities that are responsible for the elderly explaining the benefits of Product A and improved versions which are to become available in the near future

#8

 Introduce new methods of delivery and marketing for Product A as follows: (a) different strength formulations (200 mg/ 160 mg/ 145 mg); (b) different delivery methods (liquid oral, chewable); (c) improved labelling and packaging highlighting the comparative benefits of Product A in treatments for the elderly and risks of using unproven alternatives

#9

 Enter into an agreement with a generic company to delay its entry of a generic version of any NEW PHARM treatment until it has satisfied NEW PHARM that the product is safe

#10

 As in #9 but make a payment of €2 million to fund R&D by a generic company

www.hoganlovells.com

Hogan Lovells (the 'firm') refers to the international legal practice comprising Hogan Lovells International LLP, Hogan Lovells US LLP, Hogan Lovells Worldwide Group (a Swiss Verein), and their affiliated businesses, each of which is a separate legal entity. Hogan Lovells International LLP is a limited liability partnership registered in England and Wales with registered number OC323639. Registered office and principal place of business: Atlantic House, Holborn Viaduct, London EC1A 2FG. Hogan Lovells US LLP, Hogan Lovells US LLP, Hogan Lovells US LLP, Hogan Lovells US LLP, is a limited liability partnership registered in the District of Columbia. The word' partner is used to refer to a member of Hogan Lovells US LLP, or a memployee or consultant with equivalent standing and qualifications, and to a partner, employee or consultant in any of their affiliated businesses who has equivalent standing. Rankings and quotes from legal directories and other sources may refer to the former firms of Hogan & Hartson LLP and Lovells LLP. Where case studies are included, results achieved to not guarantee similar outcomes for other clients. New York State Notice: Attorney Advertising. © Hogan Lovells 2010. All rights reserved.